<i>MEG3</i> improves the <i>in vivo</i> sensitivity of A549/DDP cells to cisplatin.

<p>(Fig 7A, 7B) Four weeks after initial cisplatin administration, the tumor volume and average weight of mice receiving pCDNA-<i>MEG3</i>- or empty vector-transfected A549/DDP cells were recorded. (Fig 7C) Tumor volume was calculated twice weekly after cisplatin treatment. (Fig 7D) qRT-PCR analysis of <i>MEG3</i> expression levels in tumor tissues formed from pCDNA-<i>MEG3</i>- or empty vector-transfected A549/DDP cells. (Fig 7E) Tumors developed from pCDNA-<i>MEG3</i>-transfected A549/DDP cells showed lower PCNA protein levels, higher p53 protein expression, and lower Bcl-xl protein expression than those developed from control cells. Upper: H&E staining; second, third row and lower: immunostaining. Original magnification, ×100 or ×200. *<i>P</i> < 0.05, ** <i>P</i> < 0.01.</p

The level of <i>MEG3</i> expression level in LAD cells.

<p>(Fig 1A) qRT-PCR analysis of <i>MEG3</i> expression levels in A549 and A549/DDP cells. (Fig 1B) MTT assay of the IC₅₀ values of A549 and A549/DDP cells to cisplatin. (Fig 1C) qRT-PCR analysis of <i>MEG3</i> expression levels following the transfection of A549/DDP cells with empty vector or pCDNA-<i>MEG3</i>. (Fig 1D) MTT assay of the IC₅₀ values of empty vector- and pCDNA-<i>MEG3</i>-transfected A549/DDP cells to cisplatin. *<i>P</i> < 0.05, ** <i>P</i> < 0.01.</p

<i>MEG3</i> expression levels are positively correlated with the responses of patients to cisplatin-based chemotherapy.

<p>(Fig 8A) qRT-PCR analysis of <i>MEG3</i> expression levels in cisplatin-sensitive (n = 20) and cisplatin-insensitive (n = 21) LAD tissues. (Fig 8B) Kaplan–Meier survival analysis of the association between PFS of LAD patients and <i>MEG3</i> expression (log rank <i>P</i> < 0.001). (Fig 8C) Cisplatin-sensitive tissues exhibited higher p53 and lower Bcl-xl protein expression than cisplatin-insensitive tissues. Original magnification, ×200 or ×400. ** <i>P</i> < 0.01.</p

<i>MEG3</i> overexpression impairs A549/DDP cell proliferation <i>in vitro</i>.

<p>(Fig 3A) MTT assay of A549/DDP cell proliferation with or without cisplatin. (Fig 3B) Colony formation analysis of cell proliferation in combination with increasing concentrations of cisplatin (0.0, 1.0, and 2.0 μg/ml). (Fig 3C) Flow cytometry analysis of cell cycle distribution in combination with increasing concentrations of cisplatin. *<i>P</i> < 0.05, ** <i>P</i> < 0.01.</p

Differentially expressed lncRNAs in A549/DDP cells compared with A549 cells as determined by microarray.

<p>Differentially expressed lncRNAs in A549/DDP cells compared with A549 cells as determined by microarray.</p

Knockdown of <i>MEG3</i> promotes A549 cell proliferation <i>in vitro</i>.

<p>(Fig 5A) MTT assay of the proliferation of si-NC- and si-<i>MEG3</i>-transfected A549 cells. (Fig 5B) Flow cytometry analysis of cell cycle distribution in combination with increasing concentrations of cisplatin (0.0, 1.0, and 1.5 μg/ml). *<i>P</i> < 0.05, ** <i>P</i> < 0.01.</p

Additional file 1: of Long non-coding RNA Loc554202 induces apoptosis in colorectal cancer cells via the caspase cleavage cascades

Sequence of primers. (XLSX 11 kb

Additional file 3: Figure S1. of Long non-coding RNA Loc554202 induces apoptosis in colorectal cancer cells via the caspase cleavage cascades

The relative expression levels of miR-31 following the treatment of HCT116 and DLD1 cells with pCDNA-Loc554202 and empty vector. (TIF 3, 271 kb

Additional file 2: of Long non-coding RNA Loc554202 induces apoptosis in colorectal cancer cells via the caspase cleavage cascades

Sequence of si-RNA. (XLSX 10 kb